The Impact of Twice-Daily Indacaterol/Glycopyrrolate on the Components of Health-Related Quality of Life and Dyspnea in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Overview

Journal Chronic Obstr Pulm Dis

Date 2019 Sep 21

PMID 31539467

Authors

Donald A Mahler

Edward Kerwin

Lindsey Murray

Carole Dembek

Affiliations

Soon will be listed here.

Abstract

Background: Chronic cough, dyspnea, and excessive sputum production, the characteristic symptoms of chronic obstructive pulmonary disease (COPD), can negatively affect patients' health-related quality of life (HRQoL). The fixed-dose combination of a long-acting beta2-adrenergic agonist and a long-acting muscarinic antagonist (LABA/LAMA) have been shown to improve HRQoL and COPD symptoms as measured by the St George's Respiratory Questionnaire (SGRQ) and the Transition Dyspnea Index (TDI) total scores. However, the impact of a LABA/LAMA on the individual components of HRQoL and dyspnea with daily activities is unknown.

Methods: Secondary analysis of pooled data from 2 replicate, phase 3, 12-week, randomized, placebo, and active-controlled trials of twice-daily indacaterol/glycopyrrolate (IND/GLY) were analyzed. Change from baseline in HRQoL and dyspnea was measured by SGRQ and TDI, respectively. Total and component scores were evaluated using linear mixed models. Logistic regression was used to analyze the proportion of patients achieving minimum clinically important difference. Study outcomes were further explored in patient subgroups.

Results: A total of 2038 patients from FLIGHT1/FLIGHT2 studies were evaluated. IND/GLY significantly improved SGRQ component scores (symptoms [-7.3], activity [-3.6], and impacts [-5.0]); all < 0.001 compared with placebo. IND/GLY also significantly improved symptoms scores compared with IND and GLY (-3.5 and -3.7, respectively; both < 0.001). Patients treated with IND/GLY also had significant improvements in TDI component scores compared with placebo: functional impairment (0.48), magnitude of task (0.61), and magnitude of effort (0.54); all < 0.001. All component scores were significantly higher for IND/GLY compared with IND and GLY ( ≤ 0.002 for all).

Conclusions: Twice-daily IND/GLY significantly improved total scores as well as components of HRQoL and dyspnea in patients with COPD. These data demonstrate multiple clinical benefits of LABA/LAMA maintenance therapy in the COPD population. NCT01727141 and NCT01712516.

References

Mahler D, Witek Jr T . The MCID of the transition dyspnea index is a total score of one unit. COPD. 2006; 2(1):99-103. DOI: 10.1081/copd-200050666. View

Janson C, Marks G, Buist S, Gnatiuc L, Gislason T, McBurnie M . The impact of COPD on health status: findings from the BOLD study. Eur Respir J. 2013; 42(6):1472-83. PMC: 3844139. DOI: 10.1183/09031936.00153712. View

Mahler D, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C . FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015; 192(9):1068-79. DOI: 10.1164/rccm.201505-1048OC. View

Jones P . St. George's Respiratory Questionnaire: MCID. COPD. 2006; 2(1):75-9. DOI: 10.1081/copd-200050513. View

Ford E, Murphy L, Khavjou O, Giles W, Holt J, Croft J . Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2014; 147(1):31-45. DOI: 10.1378/chest.14-0972. View

Jones P, Quirk F, Baveystock C, Littlejohns P . A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6):1321-7. DOI: 10.1164/ajrccm/145.6.1321. View

DUrzo A, Rennard S, Kerwin E, Mergel V, Leselbaum A, Caracta C . Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2015; 15:123. PMC: 4213545. DOI: 10.1186/s12931-014-0123-0. View

Mahler D . Assessment and relief of dyspnoea. Monaldi Arch Chest Dis. 1998; 53(4):466-70. View

Blinderman C, Homel P, Billings J, Tennstedt S, Portenoy R . Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Symptom Manage. 2009; 38(1):115-23. DOI: 10.1016/j.jpainsymman.2008.07.006. View

10.

Ferguson G, Karpel J, Bennett N, Clerisme-Beaty E, Gronke L, Voss F . Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017; 27(1):7. PMC: 5434778. DOI: 10.1038/s41533-016-0002-x. View

11.

Mahler D, Horowitz M . Clinical evaluation of exertional dyspnea. Clin Chest Med. 1994; 15(2):259-69. View

12.

Sullivan J, Pravosud V, Mannino D, Siegel K, Choate R, Sullivan T . National and State Estimates of COPD Morbidity and Mortality - United States, 2014-2015. Chronic Obstr Pulm Dis. 2019; 5(4):324-333. PMC: 6361472. DOI: 10.15326/jcopdf.5.4.2018.0157. View

13.

Kentson M, Todt K, Skargren E, Jakobsson P, Ernerudh J, Unosson M . Factors associated with experience of fatigue, and functional limitations due to fatigue in patients with stable COPD. Ther Adv Respir Dis. 2016; 10(5):410-24. PMC: 5933621. DOI: 10.1177/1753465816661930. View

14.

Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G . Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014; 2(6):472-86. DOI: 10.1016/S2213-2600(14)70065-7. View

15.

Greenlund K, Liu Y, Deokar A, Wheaton A, Croft J . Association of Chronic Obstructive Pulmonary Disease With Increased Confusion or Memory Loss and Functional Limitations Among Adults in 21 States, 2011 Behavioral Risk Factor Surveillance System. Prev Chronic Dis. 2016; 13:E02. PMC: 4708003. DOI: 10.5888/pcd13.150428. View

16.

Kochanek K, Murphy S, Xu J, Arias E . Mortality in the United States, 2016. NCHS Data Brief. 2018; (293):1-8. View

17.

Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(5 Pt 1):1418-22. DOI: 10.1164/ajrccm.157.5.9709032. View

18.

Donohue J, Maleki-Yazdi M, Kilbride S, Mehta R, Kalberg C, Church A . Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013; 107(10):1538-46. DOI: 10.1016/j.rmed.2013.06.001. View

19.

Wheaton A, Cunningham T, Ford E, Croft J . Employment and activity limitations among adults with chronic obstructive pulmonary disease--United States, 2013. MMWR Morb Mortal Wkly Rep. 2015; 64(11):289-95. PMC: 4584881. View

20.

Liu Y, Croft J, Anderson L, Wheaton A, Presley-Cantrell L, Ford E . The association of chronic obstructive pulmonary disease, disability, engagement in social activities, and mortality among US adults aged 70 years or older, 1994-2006. Int J Chron Obstruct Pulmon Dis. 2014; 9:75-83. PMC: 3896280. DOI: 10.2147/COPD.S53676. View